**Abstract**

**Objective:** Blonanserin (Blon) is an atypical antipsychotic drug (AAPD) with comparable affinity to D~2~ and D~3~ receptors. The purpose of this study was to determine the ability of Blon to enhance cortical neurotransmitters efflux, determine the role of D~3~ antagonism in that process, and determine the role of D~3~ receptor blockade to improve the deficit in novel object recognition (NOR) in sub-chronic phencyclidine (PCP)-treated rats, a model of schizophrenia.

**Methods:** Guide cannula with dummy probes were placed to the medial prefrontal cortex (mPFC) and dorsal striatum (dSTR) for microdialysis in mice. Rats received vehicle or PCP for 7 days, followed by a 7-day washout for the NOR study. The D~3~ receptor antagonist, NGB2904 (NGB) or Blon was administered to rats 30 min prior to acquisition. Another group of rats received a combination of sub-effective doses (SED) of NGB and Blon.

**Results:** Blon increased DA, norepinephrine (NE) and ACh efflux in mPFC and dSTR. NGB increased DA and Ach, but not NE efflux, in mPFC and DA efflux in dSTR. NGB and Blo improved the scPCP-induced NOR deficit. The combination of SED NGB and Blon improved the NOR deficit.

**Conclusions:** D~3~ receptor blockade may contribute to the ability of Blon to increase cortical ACh and DA efflux, as well as to restore NOR in scPCP deficit. D~3~ receptor blockade may be an important component of the efficacy of Blon to enhance neurotransmitter efflux and improve cognitive function.
